The extracellular and intracellular effects of AGEs. In the ECM, AGEs form on a variety of different molecules, including lipids, collagen, laminin, elastin, and vitronectin. The formation of AGEs on ECM molecules alters the constitution of the matrix and increases stiffness. AGEs also activate the transforming growth factor (TGF)-β receptor to stimulate cell growth, leading to increased ECM production. AGEs that bind to RAGE on the endothelial cell surface lead to a signaling cascade, stimulating NAD(P)H oxidase and increasing ROS, p21 RAS, and MAPKs. In addition, the ligand-RAGE interaction also may stimulate signaling via p38 MAPK and Rac/Cdc. A key target of RAGE signaling is NF-κB. NF-κB is translocated to the nucleus, where it increases transcription of a number of different proteins, including endothelin-1, ICAM-1, E-selectin, and tissue factor. AGE and ligands for RAGE, such as HMGB1 and S100 calgranulins, trigger inflammatory pathways. AGE may decrease NO availability by the decreased activity of NOS and by quenching NO. sAGEs activate monocytes, causing increased expression of macrophage scavenger receptor (MSR) class A receptors and CD36 receptors, leading to increased OxLDL uptake and foam cell formation. DN indicates dominant-negative.
Formation of AGEs in the ECM occurs on proteins with a slow turnover rate. Accumulation of AGEs on proteins in the ECM can cause formation of cross-links, which can “trap” other local macromolecules.9,48 AGEs can alter properties of the large matrix proteins collagen, vitronectin, and laminin, through AGE-AGE intermolecular covalent bonds, or cross-linking.48–50 AGE cross-linking on type I collagen and elastin causes an increase in the area of ECM, resulting in increased stiffness of the vasculature.5,11,51–53 Glycation results in increased synthesis of type III collagen, α3(IV) collagen, type V collagen, type VI collagen, laminin, and fibronectin in the ECM, most likely via upregulation of a transforming growth factor-β intermediate.54–57 AGEs disrupt binding of the noncollagenous domain (NC-1) to the helix-rich domain on type IV collagen from the basement membrane, inhibiting the formation of a matrix-like structure.5,58,59 Formation of AGEs on laminin results in reduced binding to type IV collagen, reduced polymer elongation, and reduced binding of heparan sulfate proteoglycan.60 Glycation of laminin and type I and type IV collagens, key molecules in the basement membrane, causes inhibited adhesion to endothelial cells for both matrix glycoproteins.51,61 In diabetic subjects, the glycation of these proteins can lead to disparities in production, growth, and secretory activity of different types of cells.51 Studies suggest that AGE formation leads to a reduction in the binding of collagen and heparan to the adhesive matrix molecule vitronectin.5 AGE-induced alterations of vitronectin and laminin may explain the reduction in binding of heparan sulfate proteoglycan, a stimulant of other matrix molecules in the vessel wall, to the diabetic basement membrane.5,49,62 In addition to the formation of AGEs on proteins, AGEs can also form on lipids, as evidenced by the increased lipid-linked AGEs in LDL samples from persons with and without diabetes.63 Glycated LDL reduces nitric oxide (NO) production and suppresses uptake and clearance of LDL through its receptor on endothelial cells.63–65
AGE Effects on Intracellular Function
AGEs also form on intracellular proteins. Intracellular AGEs change cellular properties that are critical in vascular homeostasis.66 The rate of AGE formation on intracellular proteins is slowest in the presence of glucose and more rapid with intracellular natural sugars, like fructose, glyceraldehyde-3-phopshate, and glucose-6-phosphate.5,67 Ten times more fructose-derived AGEs form after 5 days than glucose-derived AGEs in vivo.68 Intracellular AGE formation significantly increases in endothelial cells after 1 week in a hyperglycemic environment.69 Intracellularly, basic fibroblast growth factor is one of the proteins that may be glycated.70 AGE modification of this protein drastically reduces the mitogenic activity of endothelial cell cytosol by 70%.70
Circulating AGEs may interact with endothelial RAGEs, which leads to perturbation of cellular properties, such as upregulation of the transcription factor NF-κB.9,71 Activation of RAGEs by AGEs transduces multiple signals, such as NAD(P)H oxidase, p21ras, the mitogen-activated protein kinases (MAPKs), extracellular signal–regulated kinase 1/2 and p38, and the GTPases Cdc42 and Rac, resulting in activation and translocation of nuclear transcription factors, including NF-κB, which transcribes its target genes (the Figure).72–75 Among these are endothelin-1, vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin, tissue factor, thrombomodulin, vascular endothelial growth factor (VEGF), and likely, proinflammatory cytokines, including IL-1α, IL-6, and tumor necrosis factor-α, and RAGE itself.76,77 Blockade of RAGE with anti-RAGE IgG or soluble RAGE (sRAGE), the extracellular ligand, inhibits NF-κB activation.8
AGE and the Endothelial Cell
sAGEs are chemotactic for human blood monocytes both in vitro and in vivo.78,79 AGEs on the subendothelium induce monocyte migration across an endothelial cell monolayer.79 In human umbilical vein endothelial cells, inhibitors of NF-κB greatly reduce high glucose–induced monocyte adhesion, suggesting that the activation of NF-κB is essential in AGE-induced monocyte adhesion and migration.78 Activation of RAGE by AGEs increases endothelial permeability to macromolecules, yet another receptor-mediated effect of AGEs on the diabetic vasculature.23,71 AGEs located on proteins, in addition to immobilized AGEs on the subendothelium, bind RAGE on the endothelium to induce hyperpermeability.77 Administration of sRAGE inhibits vascular leakage in the intestine and skin of streptozotocin-treated rats.8 AGE-bound RAGE on the endothelium also results in alteration of the cell surface structure, from that of an anticoagulant to a procoagulant endothelium, via reduced thrombomodulin activity concomitant with increased tissue factor expression.71,77,80
AGE and the Macrophage
Whereas sAGEs activate monocytes, AGEs located in basement membranes inhibit monocyte migration, inducing a process called “apoptaxis.” AGEs may contribute to the expression of oxidized LDL (OxLDL) receptors in human monocyte–derived macrophages.81 AGEs have been shown to induce gene expression of 2 important OxLDL receptors: macrophage scavenger receptor class A and CD36.81 The increased expression of these receptors leads to enhanced OxLDL uptake, resulting in foam cell transformation (the Figure). Activation of monocytes by AGE-modified human serum albumin also leads to expression of IL-1β and tumor necrosis factor-α mRNA.82 AGEs also alter cellular coagulant properties, partly via the monocyte-produced procoagulant, tissue factor, and decreased expression of the endothelial anticoagulant cofactor, thrombomodulin.23,71,80,83,84
AGE and the Smooth Muscle Cell
Addition of AGE-albumin to rat pulmonary artery smooth muscle cells results in increased levels of GTP-bound p21ras and activation of ERK1 and ERK2 (ie, MAPKs), whereas addition of nonglycated albumin to the same type of cells yields basal levels of GTP-bound p21ras and nonactivated MAPKs.85 p21ras is critical for signal transduction of AGEs, as evident when Cys118, a molecular target of ROS on p21ras, is mutated and overexpressed in PC12 cells expressing RAGE. The mutated PC12 cells are nonresponsive to AGE-albumin, whereas the wild-type cells respond to AGE-albumin by activating ERK 1/2 kinases.85
AGE Effects on NO
AGEs reduce the bioavailability and activity of endothelium-derived NO (Figure). Because NO inhibits many of the mechanisms that contribute to atherosclerosis, such as leukocyte adhesion to the vessel wall, vascular smooth muscle growth, and platelet adhesion and aggregation, this effect of AGEs on NO may be relevant to atherogenesis.67,86,87 Indeed, Hogan et al68 have demonstrated that matrix-bound and sAGEs inhibit the antiproliferative effects of NO. Moreover, impaired vasodilation in diabetes may be a result of AGEs’ reduction of NO activity.67 The levels of serum AGEs in patients with type 2 diabetes are inversely related to the degree of endothelium-dependent and endothelium-independent vasodilation.88 Several mechanisms by which AGEs reduce or block NO activity have been proposed. One mechanism suggests that AGEs reduce the half-life of endothelial NO synthase (eNOS) mRNA through an increased rate of mRNA degradation and reduced eNOS activity.89 Another mechanism proposes that AGEs impair NO production via the binding of CML residues to endothelial AGE receptors, causing a reduction in phosphorylation of serine residues in eNOS, resulting in deactivation of the enzyme.90,91 AGEs also may quench and inactivate endothelium-derived NO.67,68 Also, the endothelial production of prostacyclin (PGI2) is reduced by AGEs.92 In addition to affecting the activity of these 2 major vasodilators, AGEs also enhance the expression of endothelin-1, via NF-κB, in bovine aortic endothelial cells incubated with erythrocytes from patients with type 2 diabetes.93
AGE-bound RAGE in the endothelium results in the production of reactive oxygen intermediates, triggered, at least in part, through the activation of NADPH oxidase.72,94 AGE-RAGE interaction stimulates the production of reactive oxygen intermediates, which in turn activate a range of signaling pathways, the consequences of which include activation of NF-κB.72,94,95
The Specific AGEs: CML-AGEs
AGE-RAGE–produced oxidative stress activates NF-κB and affects the transcriptional activation of numerous cytokines and adhesion molecules, many of which are closely linked to inflammation and atherosclerosis, as discussed earlier.72,96 Through the appearance of thiobarbituric acid–reactive substances (TBARS) and activation of NF-κB, mononuclear phagocytes are also affected by oxidative processes resulting from the presence of AGEs. In addition, AGEs found on the surface of erythrocytes can bind to RAGE, increasing TBARS levels and activating NF-κB. The source of ROS on diabetic erythrocytes is most likely AGEs bound to the erythrocyte surface, because engagement of RAGE by antibodies does not produce oxidant stress.97 In mice infused with AGE-albumin, the induction of oxidant stress leads to activation of NF-κB, induction of heme oxygenase mRNA, and TBARS in the tissues.72
Anti-AGE Therapies
A variety of different compounds that inhibit AGEs have been under investigation. Aminoguanidine is a hydrazine compound that prevents AGE formation.72 Aminoguanidine reacts mostly with derivatives of early glycation products that are not bound on proteins, like 3-deoxyglucosone.72 Several avenues of investigation have suggested that aminoguanidine favorably affects vascular structure in experimental models of diabetes. The reduction of AGE formation by aminoguanidine attenuates the effects of diabetes on large arteries.52 Aminoguanidine treatment increases arterial elasticity as measured by aortic input impedence, static compliance, and left ventricular afterload in diabetic rats.52 Aminoguanidine reduces ECM accumulation of both fibronectin and laminin in streptozotocin-induced diabetic rats with diabetic nephropathy.98 In addition, aminoguanidine decreases vascular AGE accumulation and the severity of atherosclerotic plaque in diabetic rats.99 Aminoguanidine is also an NOS inhibitor, which may offset some of its benefits as an AGE inhibitor.67,100 In a placebo-controlled, randomized trial in patients with type 1 diabetes mellitus, aminoguanidine caused a slower reduction in glomerular filtration rate. Aminoguanidine reduced 24-hour urinary proteinuria and progression of retinopathy.101 However, aminoguanidine did not attenuate the time to doubling of serum creatinine.101
N-(2-Acetamidoethyl)hydrozinecarboximidamide hydrochloride (ALT-946) has been shown to be an effective inhibitor of AGE-induced cross-links.102 Like aminoguanidine, ALT-946 also inhibits NOS, though less so than aminoguanidine.102 Like aminoguanidine, (±)-2-isopropylidenehydrazono-4-oxothiazolidin-5-ylacetanidide (OPB-9195) is constructed to prevent alteration of nucleophilic residues in proteins by trapping carbonyl intermediates.103 One study has shown that administration of OPB-9195 to hypertensive rats lowered levels of glycated albumin and increased urinary NO excretion and expression of eNOS mRNA when compared with control rats.104
4,5-Dimethyl-3-phenacylthiozolium chloride (ALT-711) is a compound that breaks the cross-links of AGEs. It has a thiazolium structure that is able to sever α-carbonyl compounds by breaking the carbon-carbon bonds between carbonyls.53,103 Diabetic rats treated for 4 months with ALT-711 show reduced collagen III, increased collagen solubility, and reduced RAGE and AGE-R3 mRNA expression compared with placebo.105 In addition, ALT-711 has been shown to improve left ventricular function, reduce ventricular collagen, and lengthen survival in diabetic animals, including aged animals in whom there was a large reduction of left ventricle chamber stiffness.106,107 In older humans, ALT-711 is reported to improve arterial compliance and decrease pulse pressure.53
Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) not only inhibit cholesterol production but also block synthesis of isoprenoid intermediates that function as “platforms” for several intracellular signaling molecules.108,109 Cerivastatin prevents AGE-stimulated increases in VEGF mRNA, NF-κB expression, and DNA synthesis in microvascular endothelial cells and also prevents AGE-induced angiogenesis by interfering with the intracellular AGE signal transduction pathway.109 Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers have been shown to decrease the production of reactive carbonyl precursors.110 In one study, the ACE inhibitor ramipril attenuated AGE accumulation in diabetic animals.111
sRAGE, the extracellular ligand-binding domain of RAGE, blocks AGEs from binding to RAGE, as if sRAGE were a “sponge” soaking up sAGEs.112 In doing so, sRAGE suppresses accelerated atherosclerotic lesion formation and decreases vascular hyperpermeability.112–115 Levels of AGEs and RAGE are increased in streptozotocin-treated (diabetic) apolipoprotein E–null mice that have advanced atherosclerosis by 14 weeks of age.26 Administration of sRAGE suppresses the severity of atherosclerosis to the same level as that found in euglycemic control mice.26 Blockade of RAGE by sRAGE in mice with diabetes reduces atherosclerotic lesion area, supporting the notion that RAGE is a crucial part of the development and acceleration of atherosclerosis and that sRAGE is an effective intervention.113,114,116
Pyridoxamine, the natural form of vitamin B6, is effective at inhibiting AGEs at 3 different levels.117–120 Pyridoxamine prevents the degradation of protein-Amadori intermediates to protein-AGE products.121 In diabetic rats, pyridoxamine reduces hyperlipidemia and prevents AGE formation.122–124 Pyridoxamine scavenges the carbonyl byproducts of glucose and lipid degradation. Zucker rats treated with pyridoxamine have reduced plasma levels of glyoxal, methylglyoxal, and AGEs in collagen.125,126 Benfotiamine, a lipid-soluble thiamine derivative, inhibits the AGE formation pathway.127,128 In endothelial cells, water-soluble thiamine is similar to benfotiamine in inhibiting AGE formation in high-glucose environments.128
AGEs can be absorbed through the diet.129 Foods high in protein and fat, such as meat, cheese, and egg yolk, are rich in AGEs.130 Foods high in carbohydrates have the lowest amount of AGEs. In addition, increased cooking temperatures, like broiling and frying, and increased cooking times lead to increased amounts of AGEs.131 A diet heavy in AGEs results in proportional elevations in serum AGE levels and increased AGE cross-linking in patients with diabetes.129 Conversely, dietary AGE restriction causes a 30% to 40% decrease of serum AGE levels in healthy subjects.131 Diabetic patients on a high-AGE diet have increased expression and activity of MAPK, NF-κB, and VCAM-1 compared with diabetic subjects on a low-AGE diet.132 Excretion of AGEs absorbed through the diet is suppressed in diabetic nephropathy patients compared with healthy controls.129 Patients with diabetes and renal failure who restrict dietary AGE intake demonstrate suppressed AGE-related tissue injury.130,133
Summary
AGEs form when proteins or lipids interact with aldose sugars for an extended period of time, subsequently undergoing molecular transformations that glycate the protein or lipid, thereby imparting distinct and likely maladaptive signatures in the vessel wall. In hyperglycemic environments and in natural aging, AGEs alter cell structure and function. The recognition and binding of AGEs to RAGE contribute to the microvascular and macrovascular complications of diabetes. Understanding AGE formation and biochemistry, cellular receptors for AGE, and AGE-induced effects on extracellular and intracellular functions will serve to expedite the process of finding effective therapies that block excessive accumulation of these species and their interaction with the signal transduction receptor RAGE.
Sources of Funding
This work was supported by grants from the National Institutes of Health (HL-48743) and the American Diabetes Association (1-06-CD-01). Dr Creager is the Simon C. Fireman Scholar in Cardiovascular Medicine at Brigham and Women’s Hospital.
Disclosures
None.
Footnotes
Correspondence to Mark A. Creager, MD, Brigham and Women’s Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115. E-mail mcreager@partners.org
References